Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 5/20 | 0.56 |
| ▸ | PDE3A | Q14432 | 7/20 | 0.55 |
| ▸ | PDE3B | Q13370 | 6/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | PDE10A | Q9Y233 | 9/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | BACE1 | P56817 | 1/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14599439 | 0.90 | PDE10A (0.62) | ENPP1PDE3APDE3BPDE10AACHE | |
| Trifluoroacetic Acid SCHEMBL5525772 | 0.86 | ENPP1 (0.58) | ENPP1PDE3APDE3BMAPK1PDE10A | |
| SCHEMBL5525778 | 0.85 | ENPP1 (0.56) | ENPP1PDE3APDE3BMAPK1PDE10A | |
| SCHEMBL5070354 | 0.85 | ENPP1 (0.61) | ENPP1PDE3APDE3BMAPK1PDE10A | |
| Trifluoroacetic Acid SCHEMBL4965755 | 0.84 | ENPP1 (0.64) | ENPP1PDE3APDE3BMAPK1PDE10A | |
| Trifluoroacetic Acid SCHEMBL5528683 | 0.84 | ENPP1 (0.63) | ENPP1PDE3APDE3BMAPK1PDE10A | |
| SCHEMBL5528687 | 0.81 | ENPP1 (0.60) | ENPP1PDE3APDE3BMAPK1PDE10A | |
| SCHEMBL4966752 | 0.80 | ENPP1 (0.56) | ENPP1PDE3APDE3BMAPK1PDE10A | |
| Trifluoroacetic Acid SCHEMBL29589546 | 0.80 | ENPP1 (0.57) | ENPP1PDE3APDE3BMAPK1PDE10A | |
| Trifluoroacetic Acid SCHEMBL4984298 | 0.79 | PDE10A (0.84) | PDE3APDE3BPDE10AACHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101242838-A | Synergistic modulation of FLT3 kinase using aminoquinoline and aminoquinazoline kinase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-13 | — | — | CN | disclosed |
| EP-1893206-A2 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-05 | — | — | EP | disclosed |
| US-20070004763-A1 | AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-04 | — | — | US | disclosed |
| WO-2006135636-A2 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | WO | disclosed |
| US-20060281771-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281771-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | FLT3, CDC42BPG, PRKCQ | ENPP1 1922/4885PDE3A 3303/4885PDE3B 2347/4885 |
| US-20070004763-A1 | AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | FLT3, BMX, ABL1 | ENPP1 2497/4885PDE3A 1892/4885PDE3B 1450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.